Abstract: Provided herein are genetically engineered bacteria that are native to a host insect microbiome. Further provided are methods of inducing RNA interference in an insect, such as a bee, by administering the genetically engineered bacteria.

Abstract: A computer-implemented method, system and computer program product for compressing video. A set of video frames is partitioned into two subsets of different types of frames, a first type and a second type. The first type of frames of videos is compressed to generate a first representation by a first stage encoder. The first representation is then decoded to reconstruct the first type of frames using a first stage decoder. The second type of frames of video is compressed to generate a second representation that only contains soft edge information by a second stage encoder. A generative model corresponding to a second stage decoder is then trained using the first representation and the reconstructed first type of frames by using a discriminator employed by a machine learning system. After training the generative model, it generates reconstructed first and second types of frames using the soft edge information.

Abstract: Provided herein are therapeutic peptides. In some aspects, therapeutic peptides are provided that can alter EphB4/EFNB2 signaling and can be used to treat a cancer. In some embodiments, the peptides are comprised in nanoparticles, such as core-cross-linked polymeric micelles (CCPM).

Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

Abstract: Exemplary embodiments of the present disclosure apparatus and methods that provide for subtractive material processing, including efficient and precise ablation of tissues. Certain embodiments include a first laser configured to direct a first pulse of energy at a first wavelength to a region of tissue; a second laser configured to direct a second pulse of energy at a second wavelength to the region of tissue; and a control system configured to control operation of the first laser and the second laser.

Abstract: In some aspects, the present disclosure provides vaccine compositions comprising an antigen and a diblock copolymer wherein the diblock copolymer is pH responsive. In some embodiments, these compositions activate the STING and/or the interferon receptor pathways. In some embodiments, the diblock copolymer hits a pKa from about 6 to about 7.5. Also provided herein are methods of treatment using these compositions to treat an infectious disease or cancer.

Abstract: A highly effective synthetic route to produce donor-acceptor azetines through the highly enantioselective [3+1]-cycloaddition of silyl-protected enoldiazoacetates with aza-ylides using chiral copper(I) catalysis is provided. In one embodiment, the 2-azetidine cycloaddition products undergo generation of 3-azetidinones by reactions with nucleophiles that produce a broad spectrum of peptide products by the retro-Claisen reaction provided by facile strain with high efficacy and complete retention of enantiopurity. This ring opening reaction uncovers a new methodology for the attachment of chiral peptide units to a variety of amines and alcohols, and tolerates a broad scope of nucleophiles including naturally occurring amines, alcohols, amino acids, and other nitrogen based nucleophiles.

Abstract: A method of fabricating amorphous iridium oxide film pH sensors and microfluidic devices incorporating the pH sensors. The present invention provides a fabrication method for sol-gel based iridium oxide (IrOx) thin film pH sensors and microelectrodes. The invention further provides microelectrode arrays produced by the fabrication methods and microfluidic devices including the microelectrodes and microelectrode arrays. In one aspect, the invention is a method for fabricating a microelectrode pH sensor.

Abstract: Methods for treating Shiga toxicosis, caused by infection with Shiga toxin bacteria, are provided. The methods include administering to a subject in need thereof an effective amount of one or more active agents selected from tamoxifen, 4-hydroxytamoxifen, endoxifen, toremifene, raloxifene, bazedoxifene, and pharmaceutically acceptable salts thereof. In some embodiments, the methods further include the administration of an antibiotic or a manganese compound to the subject. Pharmaceutical compositions for the treatment of Shiga toxicosis are also described.

Abstract: The present disclosure provides methods and formulations for treating a patient suffering from one or more of chronic inflammatory injury, metaplasia, dysplasia or cancer of an epithelial tissue, which method comprises administering to the patient an agent that selectively kills or inhibits the proliferation or differentiation of pathogenic epithelial stem cells (PESCs) relative to normal epithelial stem cells in the tissue in which the PESCs are found. Representative epithelial tissues include pulmonary, genitourinary, gastrointestinal/esophageal, pancreatic and hepatic tissues.

Abstract: The present disclosure provides methods of inhibiting PARG in cancer cells, including methods comprising administering a PARG inhibitor that modulates position Tyr795 in PARG. Also provided herein are methods of treating and/or preventing cancer comprising administering a PARG inhibitor. In some embodiments, the PARG inhibitors are of the formula: wherein the variables are defined herein.

Abstract: The current methods and compositions of the disclosure provide a platform for detecting the transcriptomic, genomic, or proteomic profile in relation to particular characteristics of a single cell, such as the location of a cell within a tissus. Accordingly, aspects of the disclosure relate to a method for barcoding eukaryotic cell nuclei comprising: transferring oligonucleotides into the nuclei of cells and performing single-cell analysis to identify the sequence of the barcode; wherein the oligonucleotides comprise a barcode region and a target region.

Abstract: Disclosed herein are compounds of structural Formula VIIa or VIIb: or a pharmaceutically acceptable salt thereof, and compositions thereof useful in the treatment of GLS1 mediated diseases, such as cancer. Methods of inhibition GLS1 activity in a human or animal subject are also provided.

Abstract: Crosslinkers of an amide or thiocarbamate of 7-nitroindoline were prepared with at least two attached reactive groups for crosslinking capability. The photo-cleavability of the invented crosslinkers is based on the known photolysis behavior of N-acyl-7-nitroindolines, and the photolysis behavior of amides and thiocarbamates of 7-nitroindolines. These crosslinkers enable crosslinking of biopolymers, which can be reversed by illumination with light.

Abstract: Methods are described for generating autologous tissue grafts, including generating grafts at the point of care, which include isolated cell populations that are enriched with stem cells and are mixed with biological fillers including hyaluronic acid and derivatives thereof. The hyaluronic acid localizes the cells to a desired injection site and stimulates collagen production thus enhancing the viability and the longevity of the graft.

Abstract: A cartridge comprises a housing; a sample mixing compartment disposed within the housing, the sample mixing compartment comprising: an activation pouch, and a sample collection region; and a gas transporter tube having a first end and a second end, the tube being disposed within the housing adjacent to the sample mixing compartment, wherein the sample mixing compartment is partially defined by a moveable door of the housing, the moveable door providing access to the sample mixing compartment when the door is in an open position and preventing access to the sample mixing compartment when the door is in a closed position; and wherein the door is configured to release contents of the activation pouch upon movement from the open position to the closed position.

Abstract: Provided herein are methods of predicting whether a pancreatic cancer patient will be a short-term or long-term survivor based on their intra-tumoral microbiota. Also provided are methods of treating pancreatic cancer patients using fecal microbial transfer from long-term pancreatic cancer survivors as well as pharmaceutical compositions comprising fecal microbiota obtained from long-term pancreatic cancer survivors.

Abstract: The present disclosure provides methods of treating cancer in a patient determined to have osimertinib resistant EGFR mutations by administering a second-generation quinazolinamine derivative tyrosine kinase inhibitor.

Abstract: Disclosed herein are methods of manipulating particles on solid substrates via optothermally-gated photon nudging.

Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of disease, including cancer.